Topics / Clinical Trials

Weekly issue

Clinical Trials Papers of the Week

The top Clinical Trials papers of the week: the 20 most important new papers of the past week, ranked by potential impact. A new issue comes out every Monday, covering the previous Monday-to-Sunday week.

Nov 9 - 15, 2026 · Updated

Prefer new papers every day? It's free.Clinical Trials Daily Papers →
  1. 1
    Obesity Pharmacotherapies and Cognition

    This Review examines the evidence across cardiometabolic disease, aging, and Alzheimer's disease, focusing on glucagon-like peptide-1 (GLP-1)-based therapies and combination approaches that engage glucose-dependent insulinotropic polypeptide, glucagon, and amylin pathways.

  2. 2
    Lipid Homeostasis and Cellular Metabolism in Neurodegenerative Diseases: A Maturing Framework to Guide Therapeutic Development

    We present an integrated framework where correcting lipid imbalances and metabolic dysregulation may complement or obviate protein-targeted approaches, creating more precise clinical trials and combination strategies.

  3. 3
    Efficacy and Safety of Anti-tau Drugs for Alzheimer's Disease: A Systematic Review and Network Meta-analysis

    Network analysis revealed that MAPT and nicotinamide ranked highest for improving cognitive function, and gosuranemab ranked highest for tau biomarker changes.

  4. 4
    From Folate to The Epigenetic Clock: One-carbon Metabolism in Oocyte Quality and Ovarian Ageing

    This review examines OCM in oocyte development, epigenetic regulation, and ovarian ageing, focusing on substrate supply, enzyme regulation, and methyl-donor metabolism.

  5. 5
    Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA)

    Trial 1 included patients not receiving positive airway pressure treatment and trial 2 included patients receiving positive airway pressure treatment.

Get papers like these the day they come out, not a week later.

Follow this category
  1. 6
    Seladelpar for Alkaline Phosphatase Normalization in Primary Biliary Cholangitis: The IDEAL Phase III Randomized Controlled Trial

    However, elevation in ALP below this threshold has been shown to increase the risk of disease progression, especially in patients with additional risk factors. We evaluated the effect of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist approved for PBC, on ALP normalization when levels are above normal but <1.67× ULN.

  2. 7
    Effects of Lactobacillus Crispatus -Containing Probiotics and Metformin on Insulin Resistance, Inflammation, and Gut Microbiome in Polycystic Ovary Syndrome: Protocol for An Open-Label Randomized Controlled Trial

    This study aims to compare probiotic, metformin, and combination therapy for reducing insulin resistance in PCOS over 12 weeks and assess their effects on gut barrier integrity, microbiome composition, hyperandrogenemia, glycemic control, and clinical outcomes.

  3. 8
    Tarlatamab for Treatment of Small Cell Lung Cancer in Clinical Practice: A Multicenter U.S. Retrospective Cohort Study from The ONWARD Consortium

    Real-world data on efficacy and safety of tarlatamab in small cell lung cancer (SCLC) remains limited. This retrospective study analyzed 265 tarlatamab-treated patients across 11 U.S. centers in the ONWARD-SCLC consortium (11/2023-4/2025), evaluating clinical outcomes, CRS, ICANS, and impact of prophylactic medications.

  4. 9
    A Single Preemptive Dose of Intravenous Nefopam Augmenting Multimodal Analgesia for Total Knee Arthroplasty: A Prospective, Triple-Blind, Randomized Controlled Trial

    We hypothesized that a single preemptive dose of intravenous (IV) nefopam would optimize postoperative pain control, reduce opioid consumption, and accelerate functional recovery in TKA.

  5. 10
    Pharmacotherapy for Older Adults with Cancer: A Digest of The Japanese Clinical Practice Guidelines (2nd Edition) - Lung Cancer

    This article presents an English digest of the second edition of the Japanese Clinical Practice Guidelines for Pharmacotherapy in Older Adults with Cancer, focusing on lung cancer.

  6. 11
    Resistance Exercise to Attenuate Lean Mass Loss During Tirzepatide Therapy for Obesity: A Randomized Controlled Trial

    Incretin mimetics as obesity therapy induce substantial weight and fat loss but also decrease lean soft tissue mass, possibly impairing skeletal muscle function. Here, in this two-arm randomized controlled trial of adding resistance exercise (REx) to tirzepatide (T), 120 adults with overweight or obesity were treated with tirzepatide and randomized to thrice-weekly resistance exercise training or usual activities for 40 weeks.

  7. 12
    The IgG4ward! Foundation Guidelines on The Treatment of IgG4-related Disease

    This effort provides cohesive, consensus-based guidelines from a geographically and professionally diverse group of experts in IgG4-related disease, reflecting the evolution in the field since 2015.

  8. 13
    Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development (LATENT): A Randomized Controlled Trial

    Electrocardiographic analysis aided by artificial intelligence (AI) may identify atrial electrical vulnerability during sinus rhythm.

  9. 14
  10. 15
    Phase 3 Clinical Development of Semaglutide (2015-2026): A Comprehensive Evidence-based Review of Trial Designs, Therapeutic Outcomes and Global Clinical Experience

    This review critically evaluates Phase 3, Phase 3a, and Phase 3b clinical trials (CTs) assessing the efficacy, safety and therapeutic utility of semaglutide, with an emphasis on the SUSTAIN, PIONEER, STEP, SELECT, FLOW, SOUL and related programmes.

  11. 16
    Survival in Patients with Renal Cell Carcinoma and Brain Metastases: An Update of The Renal Graded Prognostic Assessment

    This study aimed to determine if survival has changed since the introduction of current therapies, identify prognostic factors, update the prognostic index (the Renal Graded Prognostic Assessment [GPA]) in the context of contemporary multi-modal therapies, compare outcomes with legacy cohorts, and determine whether overall survival correlates with intracranial progression-free survival.

  12. 17
    Impact of Dosage Modifications on Efficacy: Insights from Select Tyrosine Kinase Inhibitors Approved for Treatment of Non-Small Cell Lung Cancer with EGFR Mutations

    Here, we explored the impact of dosage modifications on progression free survival (PFS) and overall survival (OS) for four US FDA-approved tyrosine kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations.

  13. 18
    Cardiac and Vascular Involvement in Protein Misfolding Diseases

    In this Review, we outline how the failure of proteostasis drives oligomer toxicity, amyloid deposition and inflammation in cardiovascular tissues as well as microvascular injury and thrombosis, which culminate in cardiovascular dysfunction.

  14. 19
    Impact of Neoadjuvant Carboplatin in Early-Stage Triple-Negative Breast Cancer: A Pooled Analysis of The BrighTNess, Cancer and Leukemia Group B 40603 (Alliance), and GeparSixto Clinical Trials

    To better characterize the therapeutic benefits of the addition of carboplatin to anthracycline- and taxane-based neoadjuvant chemotherapy (NACT) in early-stage triple-negative breast cancer (TNBC), we performed a pooled analysis of three randomized clinical trials: BrighTNess (NCT02032277), CALGB 40603 (NCT00861705), and GeparSixto (NCT01426880).

  15. 20